18F-Psma-1007

4 trials 2 recruiting

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

2 Recruiting

2 Completed trials

5 Sponsors

4 Countries

Phase III

Phase II/III

Phase II

Phase III/IV

Phase III: 1 Phase II/III: 1 Phase II: 1 Phase III/IV: 1

Indications tested

Prostate cancer 1

Sponsors using this IMP

Canisius Wilhelmina Ziekenhuis 1 Region Vaesterbotten 1 Stichting Radboud University Medical Center 1 Turku University Hospital 1 Umea University 1

All trials

4 total

Evaluation of PSMA-PET and mpMRI in high-risk prostate cancer – using histopathologic validation Recruiting

2022-501892-14-00 Phase III 1 country Region Vasterbotten; Umea University
99mTc-MIP-1404 SPECT/CT for primary PROstate cancer STAging: comparative prospective, randomized trial to present guideline imaging, PROSTAM… Recruiting

2024-516083-28-00 Phase II/III 1 country Turku University Hospital
Multi-institutional Evaluation of the Cost-effectiveness of PSMA-PET/CT for the Detection of Pelvic Lymph Node Invasion in Newly Diagnosed P… Ended

2024-518171-59-00 Phase III/IV 1 country Canisius Wilhelmina Ziekenhuis
Lutetium-177-PSMA in Oligo-metastatic Hormone Sensitive Prostate Cancer. Ended

2023-509881-39-00 Phase II 2 countries Stichting Radboud University Medical Center

Showing 1–4 of 4 trials

← All drugs A–Z